Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory D Lewis

Showing results (231-240 of 270) with videos related to

Pageof 27
Sort By:
JAMA Cardiology|November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical TrialDouglas L Mann, Michael M Givertz, Justin M Vader, et al.
JAMA Cardiology|March 17, 2021
Metabolic Cost of Exercise Initiation in Patients With Heart Failure With Preserved Ejection Fraction vs Community-Dwelling AdultsRavi V Shah, Mark W Schoenike, Miguel Á Armengol de la Hoz, et al.
JAMA|May 17, 2017
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical TrialGregory D Lewis, Rajeev Malhotra, Adrian F Hernandez, et al.
European Journal of Heart Failure|May 1, 2021
Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findingsSara Hadzibegovic, Alessia Lena, Timothy W Churchill, et al.
Circulation|April 13, 2012
Metabolite profiling identifies pathways associated with metabolic risk in humansSusan Cheng, Eugene P Rhee, Martin G Larson, et al.
JACC. Cardiovascular Interventions|April 25, 2020
Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility StudyAlexander M K Rothman, Jean-Luc Vachiery, Luke S Howard, et al.
JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
JAMA Internal Medicine|December 1, 2015
Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk: The Coronary Artery Risk Development in Young Adults (CARDIA) StudyRavi V Shah, Venkatesh L Murthy, Laura A Colangelo, et al.
Pageof 27

Showing results (231-240 of 270) with videos related to

Sort By:
Pageof 27
JAMA Cardiology|November 3, 2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical TrialDouglas L Mann, Michael M Givertz, Justin M Vader, et al.
JAMA Cardiology|March 17, 2021
Metabolic Cost of Exercise Initiation in Patients With Heart Failure With Preserved Ejection Fraction vs Community-Dwelling AdultsRavi V Shah, Mark W Schoenike, Miguel Á Armengol de la Hoz, et al.
JAMA|May 17, 2017
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical TrialGregory D Lewis, Rajeev Malhotra, Adrian F Hernandez, et al.
European Journal of Heart Failure|May 1, 2021
Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findingsSara Hadzibegovic, Alessia Lena, Timothy W Churchill, et al.
Circulation|April 13, 2012
Metabolite profiling identifies pathways associated with metabolic risk in humansSusan Cheng, Eugene P Rhee, Martin G Larson, et al.
JACC. Cardiovascular Interventions|April 25, 2020
Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility StudyAlexander M K Rothman, Jean-Luc Vachiery, Luke S Howard, et al.
JACC. Heart Failure|July 10, 2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE TrialDouglas L Mann, Stephen J Greene, Michael M Givertz, et al.
Journal of the American College of Cardiology|September 1, 2024
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCharles F Sherrod, Sara Saberi, Michael E Nassif, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
JAMA Internal Medicine|December 1, 2015
Association of Fitness in Young Adulthood With Survival and Cardiovascular Risk: The Coronary Artery Risk Development in Young Adults (CARDIA) StudyRavi V Shah, Venkatesh L Murthy, Laura A Colangelo, et al.
Pageof 27